Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
<b>Background/Objectives</b>: Traditional paclitaxel therapy often results in significant side effects due to its non-specific targeting of cancer cells. Peptide aptamer–paclitaxel conjugates present a promising alternative by covalently attaching paclitaxel to a versatile peptide aptame...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/40 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587706779041792 |
|---|---|
| author | Xinyang Shen Yuan Ma Hang Luo Razack Abdullah Yufei Pan Yihao Zhang Chuanxin Zhong Baoting Zhang Ge Zhang |
| author_facet | Xinyang Shen Yuan Ma Hang Luo Razack Abdullah Yufei Pan Yihao Zhang Chuanxin Zhong Baoting Zhang Ge Zhang |
| author_sort | Xinyang Shen |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Traditional paclitaxel therapy often results in significant side effects due to its non-specific targeting of cancer cells. Peptide aptamer–paclitaxel conjugates present a promising alternative by covalently attaching paclitaxel to a versatile peptide aptamer via a linker. Compared to antibody–paclitaxel conjugates, peptide aptamer–paclitaxel conjugates offer several advantages, including a smaller size, lower immunogenicity, improved tissue penetration, and easier engineering. <b>Methods</b>: This review provides an in-depth analysis of the multifunctional peptide aptamers in these conjugates, emphasizing their structural features, therapeutic efficacy, and challenges in clinical applications. <b>Results</b>: This analysis highlights the potential of peptide aptamer–paclitaxel conjugates as a novel and effective approach for targeted cancer therapy. By harnessing the unique properties of peptide aptamers, these conjugates demonstrate significant promise in improving drug delivery efficiency while reducing the adverse effects associated with traditional paclitaxel therapy. <b>Conclusions</b>: The incorporation of peptide aptamers into paclitaxel conjugates offers a promising pathway for developing more efficient and targeted cancer therapies. However, further research and clinical studies are essential to fully unlock the therapeutic potential of these innovative conjugates and enhance patient outcomes. |
| format | Article |
| id | doaj-art-45c242080ebd4c39bc16d187d88870d4 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-45c242080ebd4c39bc16d187d88870d42025-01-24T13:45:40ZengMDPI AGPharmaceutics1999-49232024-12-011714010.3390/pharmaceutics17010040Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted TherapyXinyang Shen0Yuan Ma1Hang Luo2Razack Abdullah3Yufei Pan4Yihao Zhang5Chuanxin Zhong6Baoting Zhang7Ge Zhang8Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, ChinaSchool of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, ChinaSchool of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, ChinaSchool of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, ChinaSchool of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China<b>Background/Objectives</b>: Traditional paclitaxel therapy often results in significant side effects due to its non-specific targeting of cancer cells. Peptide aptamer–paclitaxel conjugates present a promising alternative by covalently attaching paclitaxel to a versatile peptide aptamer via a linker. Compared to antibody–paclitaxel conjugates, peptide aptamer–paclitaxel conjugates offer several advantages, including a smaller size, lower immunogenicity, improved tissue penetration, and easier engineering. <b>Methods</b>: This review provides an in-depth analysis of the multifunctional peptide aptamers in these conjugates, emphasizing their structural features, therapeutic efficacy, and challenges in clinical applications. <b>Results</b>: This analysis highlights the potential of peptide aptamer–paclitaxel conjugates as a novel and effective approach for targeted cancer therapy. By harnessing the unique properties of peptide aptamers, these conjugates demonstrate significant promise in improving drug delivery efficiency while reducing the adverse effects associated with traditional paclitaxel therapy. <b>Conclusions</b>: The incorporation of peptide aptamers into paclitaxel conjugates offers a promising pathway for developing more efficient and targeted cancer therapies. However, further research and clinical studies are essential to fully unlock the therapeutic potential of these innovative conjugates and enhance patient outcomes.https://www.mdpi.com/1999-4923/17/1/40cancerpaclitaxelpeptide aptamerpeptide aptamer–paclitaxel conjugatetherapeutic effect |
| spellingShingle | Xinyang Shen Yuan Ma Hang Luo Razack Abdullah Yufei Pan Yihao Zhang Chuanxin Zhong Baoting Zhang Ge Zhang Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy Pharmaceutics cancer paclitaxel peptide aptamer peptide aptamer–paclitaxel conjugate therapeutic effect |
| title | Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy |
| title_full | Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy |
| title_fullStr | Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy |
| title_full_unstemmed | Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy |
| title_short | Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy |
| title_sort | peptide aptamer paclitaxel conjugates for tumor targeted therapy |
| topic | cancer paclitaxel peptide aptamer peptide aptamer–paclitaxel conjugate therapeutic effect |
| url | https://www.mdpi.com/1999-4923/17/1/40 |
| work_keys_str_mv | AT xinyangshen peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT yuanma peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT hangluo peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT razackabdullah peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT yufeipan peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT yihaozhang peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT chuanxinzhong peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT baotingzhang peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy AT gezhang peptideaptamerpaclitaxelconjugatesfortumortargetedtherapy |